Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip super([registered])

Safety data on the inactivated split influenza vaccine, Vaxigrip super([registered]), were compiled and analysed from 28 clinical trials (total: 4599 subjects aged 6 months to 99 years) to provide a robust estimate of the reactogenicity profile. The most frequent solicited reactions were non- severe...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2006-03, Vol.24 (10), p.1586-1592
Main Authors: Delore, Valentine, Salamand, Camille, Marsh, Grenville, Arnoux, Sabine, Pepin, Stephanie, Saliou, Pierre
Format: Article
Language:English
Subjects:
Influenza virus
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Safety data on the inactivated split influenza vaccine, Vaxigrip super([registered]), were compiled and analysed from 28 clinical trials (total: 4599 subjects aged 6 months to 99 years) to provide a robust estimate of the reactogenicity profile. The most frequent solicited reactions were non- severe injection site pain and erythema in children, adults, and elderly. Mild or moderate fever was the most frequent reaction in 6-36 months olds; few systemic reactions were reported in older groups. Reactogenicity was comparable in healthy and high-risk children. The long-term experience with the world's most widely used influenza vaccine, Vaxigrip super([registered]), confirms its excellent tolerability, and supports its continued use in clinical practice worldwide.
ISSN:0264-410X
DOI:10.1016/j.vaccine.2005.10.008